Anti-inflammatory Therapeutics Asia-Pacific
Market Research Report, 2014-2020
Published Date:
June - 2015
Report Code:
1563
The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR
of 8.6% over the forecast period, owing to the rising healthcare expenditure,
disposable income of individuals, increasing popularity of biologics and better
healthcare access. Increase in the number of autoimmune and respiratory diseases,
new drugs in development pipeline and increased usage of OTC NSAIDs are the major
factors driving the Asia-Pacific anti-inflammatory market. Moreover, increasing
awareness of anti-inflammatory biologics and favorable government initiatives in the
Asia-Pacific region are expected to drive the market during the analysis period. Factors,
such as side effects of anti-inflammatory drugs and uncertain patent legislations, i.e.,
compulsory licensing in India would continue to impede the market growth.
The Asia-Pacific anti-inflammatory therapeutics market is segmented on the basis of
indication, drug class and geography. The indications considered in this report include
arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease
and other inflammatory diseases. Among indications, arthritis was the dominant
segment accounting for 41.3% of the APAC anti-inflammatory therapeutics market in
2014 and holds potential for growth during the forecast period. Anti-inflammatory
biologics are the most preferred drugs for treatment of arthritis.
On the basis of drug class, the market is segmented into anti-inflammatory biologics,
non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Antiinflammatory biologics holds the largest share among drug classes accounting for
around 50% share of the Asia-Pacific anti-inflammatory therapeutics market, and is
expected to grow rapidly during the forecast period. Geographically, the market is
segmented into six countries namely Japan, China, India, Australia, South Korea,
Indonesia and others. Among these countries, Japan holds the largest share in the AsiaPacific anti-inflammatory therapeutics market; however, China is expected to exhibit
the fastest growth during the forecast period. Major market players have adopted
strategies such as collaborations, indication expansions and product launches to
expand their market presence. In 2014, Novartis got marketing approval for the drug
Cosentyx (secukinumab) in Japan for the treatment of psoriatic arthritis. The company
has filed new patents to overcome the issues of patent expiries of their existing drugs
and to gain a prominent market share. The key companies profiled in this report are
Pfizer, Inc., AbbVie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & CO., Inc.,
Novartis AG, F. Hoffmann-La Roche AG, Eli Lily and Company, AstraZeneca PLC and
Amgen.
KEY MARKET BENEFITS
The report provides a quantitative analysis of the current market and
estimations during 20142020 that assist in identifying and capitalizing on the
prevailing market opportunities
Exhaustive analysis of the Asia-Pacific anti-inflammatory therapeutics market by
product type helps in understanding the types of therapeutics and their
categories that are currently being used to gain prominence in future
Competitive intelligence of leading manufacturers and distributors of antiinflammatory therapeutics helps in understanding the competitive scenario
across the geographies
Comprehensive analysis of factors that drive and restrict the growth of the AsiaPacific anti-inflammatory therapeutics market has been provided
SWOT analysis facilitates the study of internal environment of leading
companies for strategic decision-making
The country-wise analyses of anti-inflammatory therapeutics market conditions
have been provided in this report
Get more information of Anti-inflammatory Therapeutics Market at:
[Link]
KEY MARKET SEGMENTS
The Asia-Pacific Anti-inflammatory Therapeutics Market is segmented below:
Asia-Pacific Anti-inflammatory Therapeutics MarketBy Indication
o Arthritis
o Respiratory diseases
o Multiple sclerosis
o Psoriasis
o Inflammatory bowel disease
o Other inflammatory diseases
Asia-Pacific Anti-inflammatory Therapeutics MarketBy Drug Class
o Anti-Inflammatory Biologics
o Non-Steroidal Anti-inflammatory drugs (NSAIDs)
o Corticosteroids
Asia-Pacific Anti-inflammatory Therapeutics MarketBy Country
o Japan
o China
o India
o Australia
o South Korea
o Indonesia
o Other APAC countries
Table of Contents
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
Chapter 6
Chapter 7
Introduction
Executive Summary
Market Overview
Asia-pacific Anti-inflammatory Therapeutics Market by Indication
Asia-pacific Anti-inflammatory Therapeutics Market by Drug Class
Asia-pacific Anti-inflammatory Therapeutics Market by Country
Company Profiles
CONTACT US:
Syed Ali
Level 32, 101 Miller Street,
North Sydney, NSW 2060
Toll Free: +61-280 454 214
Landline: +91 (20) 60604041 (India)
Email: sales@[Link]
Web - [Link]